The monoclonal antibodies developed for PD‐1 and its ligands as well as CTLA4 have been approved for the clinical therapy of several cancers (eg melanoma and non‐small‐cell lung carcinoma).33, 34. This evidence concerns the gene CTLA4 and cancer.